We are pleased and proud of our achievements in 2019. We have hit our financial targets, delivered for our customers and realigned our business structure.
Albert M. Baehny, Chairman of the Board of Directors and Chief Executive Officer ad interim
Letter to Stakeholders
5.9bn
SALES IN CHF
Read more
6.8
SALES GROWTH IN %
1.6bn
CORE EBITDA IN CHF
27.4
CORE EBITDA MARGIN IN %
1.2bn
CORE EBIT IN CHF
21.0
CORE EBIT MARGIN IN %
9.1
ROIC IN %
28.5
CORE RONOA IN %
2019 was a strong year. We met our targets for revenues and margins, while making significant CAPEX investments to grow our business.
Discover more
Our goal is to enable our talent to reach their full potential, to form a single global community and to strengthen Lonza’s culture around our shared values.
As we look to 2020, we will increase significantly the number of new projects becoming operational along with the highest ever number of pre-approval inspections (PAI).
Over the course of 2019, we have seen strong and sustained demand for our services across modalities, which has resulted in 11% sales growth in Pharma Biotech & Nutrition.
Once completed, the carve-out will enable us to focus fully on our own markets and our own industry, and make even closer connections to our customer communities.
Our Strategic Focus
Talent Attraction and Retention
Pharma Biotech & Nutrition
4.2bn
Sales in CHF
Specialty Ingredients
1.7bn
